JP7139340B2 - 抗herv-kエンベロープ抗体およびその使用 - Google Patents
抗herv-kエンベロープ抗体およびその使用 Download PDFInfo
- Publication number
- JP7139340B2 JP7139340B2 JP2019539822A JP2019539822A JP7139340B2 JP 7139340 B2 JP7139340 B2 JP 7139340B2 JP 2019539822 A JP2019539822 A JP 2019539822A JP 2019539822 A JP2019539822 A JP 2019539822A JP 7139340 B2 JP7139340 B2 JP 7139340B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- herv
- env
- cdr
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 23
- 101710091045 Envelope protein Proteins 0.000 claims description 21
- 101710188315 Protein X Proteins 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 241000713887 Human endogenous retrovirus Species 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 241000192019 Human endogenous retrovirus K Species 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 78
- 210000002569 neuron Anatomy 0.000 description 73
- 102000004169 proteins and genes Human genes 0.000 description 66
- 235000018102 proteins Nutrition 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 102100034349 Integrase Human genes 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 14
- 229920001213 Polysorbate 20 Polymers 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000001537 neural effect Effects 0.000 description 12
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 210000002241 neurite Anatomy 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000011533 pre-incubation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000005714 functional activity Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 238000007913 intrathecal administration Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 206010029350 Neurotoxicity Diseases 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 206010044221 Toxic encephalopathy Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010304 firing Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000007135 neurotoxicity Effects 0.000 description 5
- 231100000228 neurotoxicity Toxicity 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001057184 Axion Species 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100034353 Integrase Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010078428 env Gene Products Proteins 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 Boc group Chemical group 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000337 motor cortex Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 231100000255 pathogenic effect Toxicity 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QUTSYCOAZVHGGT-UHFFFAOYSA-N 2,6-bis(bromomethyl)pyridine Chemical compound BrCC1=CC=CC(CBr)=N1 QUTSYCOAZVHGGT-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101100203568 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) sod2 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- XEQLGWAGMYUVTR-UHFFFAOYSA-N O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 XEQLGWAGMYUVTR-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000012193 PureLink RNA Mini Kit Methods 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 101100111809 Schizosaccharomyces pombe (strain 972 / ATCC 24843) bsu1 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 101150014554 TARDBP gene Proteins 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000007455 autophagic response Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 101150062190 sod1 gene Proteins 0.000 description 1
- 101150048620 sodN gene Proteins 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/28—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Vibrionaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
Description
本発明者らは、HERV-Kエンベロープタンパク質に対する新規な抗体を開発した。この抗体は、予想外の特性を示すものであった。
[定義]
本明細書において用いられるとき、用語「処置(treating; treatment)」とは、この用語が適用される障害または状態を、逆転させたり、緩和したり、進行を阻害したり、予防したりすることを意味する。あるいは、この用語が適用される障害または状態の1つ以上の症状を、逆転させたり、緩和したり、進行を阻害したり、予防したりすることを意味する。
(1)HERV-K-Envタンパク質に曝露されたニューロンの、ニューロン機能活性を維持する。
(2)HERV-K-Envタンパク質に曝露されたニューロンの、細胞生存率を維持する。および/または、
(3)HERV-K-Envタンパク質に曝露されたニューロンの、ニューロン形態を維持する。
(1)3つのCDRを有している可変ドメインを有する軽鎖。それぞれのCDRは、配列番号1に記載のCDR-L1、配列番号2に記載のCDR-L2、および配列番号3に記載のCDR-L3である。および、
(2)3つのCDRを有している可変ドメインを有する重鎖。それぞれのCDRは、配列番号4に記載のCDR-H1、配列番号5に記載のCDR-H2、および配列番号6に記載のCDR-H3である。
(1)3つのCDRを有している可変ドメインを有する軽鎖。それぞれのCDRは、配列番号1に記載のCDR-L1、配列番号2に記載のCDR-L2、および配列番号3に記載のCDR-L3である。および、
(2)3つのCDRを有している可変ドメインを有する重鎖。それぞれのCDRは、配列番号4に記載のCDR-H1、配列番号5に記載のCDR-H2、および配列番号6に記載のCDR-H3である。
本発明のさらなる目的は、HERV-Kエンベロープタンパク質(HERV-K-Env)に対する抗体の有効な用量と、薬学的に許容可能な賦形剤と、を含んでいる医薬組成物に関する。
他の態様において、本発明はまた、生体サンプル中のHERV-Kエンベロープ抗体を検出する方法に関する。この方法は、上記生体サンプルを、上記で定義した抗HERV-Kエンベロープ抗体と接触させる工程を含む。
一態様において、本発明はまた、ALSを患う患者を処置する方法に関する。この方法は、上記で定義したHERV-Kエンベロープタンパク質を認識する抗体の有効量を、上記患者に投与する工程を含む。
(1)生体サンプル中のHERV-Kウイルスを検出および/または定量化することによって、患者の予後を予測する工程。
(2)その後、工程(1)がヒト内在性レトロウイルス(HERV)K型の発現を示す場合に、本発明の方法は、上記患者に本発明の抗体を提供する工程を含む。
(a)本発明の抗体で患者を処置する工程。
(b)その後、上記患者の生体サンプル中のHERV-Kを検出および/または定量化する工程。
[1.材料および方法]
[1.1.モノクローナル抗体の開発]
[1.1.1.免疫化および免疫細胞の回収]
E.coli由来のhis-SUMOタグ化したHERV-K-Envタンパク質(75kDa;Mybiosourceより提供;MBS1391552)で、3匹の雌OFマウス(Charles River)を免疫化した。免疫化は、Biotem社の機密のRADプロトコル(Rapid Antibody developmentプロトコル)に従った。
D-1に、免疫不全ヌードマウス(BIOTEM)に、20%FCS(PAA, A15-251)を含有している5mLのDMEM(SIGMA, D5671)を注射した。2±1分後に、腹水由来のマクロファージを回収し、DMEM培地(SIGMA, D5671)中で培養した。
ハイブリドーマ細胞を解凍し、DMEM(SIGMA, D5671)、HT(ヒポキサンチン100μM、チミジン16μM;SIGMA H0137)、20%FCS(PAA, A15-251)、2%ハイブリドーマ増強サプリメント(HES;SIGMA, H6020)、4mM L-グルタミン(SIGMA, G7513)、1%ペニシリン/ストレプトマイシン(SIGMA, P0781)を用いて培養した。培養は、37℃、5%CO2の24ウェルプレート中にて、1週間行った。クローニングの前日に、ハイブリドーマ細胞を分割した。
maxisorp 96円錐底ウェルプレート(NUNC, 449824)を、(i)50μLの1μg/mL HERV-K-Envタンパク質(Mybiosource, MBS1391552)、(ii)E.Coli溶解物(XL1-Blue MRF, Stratagene)、(iii)1×リン酸緩衝生理食塩水(PBS;BIOTEM)中のHEK細胞溶解物で、室温にて一晩コーティングした。プレートを、[1×PBS+0.05%Tween20(VWR, 28829.296)]洗浄バッファで洗浄した(300μL/ウェル)。非特異的結合部位を、[1×PBS+0.05%Tween20+2.5%ミルク(Regilait)]ブロッキングバッファで、室温にて1時間ブロッキングした(150μL/ウェル)。プレートを、[1×PBS+0.05%Tween20]洗浄バッファで洗浄した(300μL/ウェル)。
GN_mAb_Env_K01ハイブリドーマ細胞を解凍した。最初はT75cm2組織培養フラスコ(Corning)内で、次にT300cm2組織培養フラスコ(Corning)内で培養した。最後に、10×106の細胞を10組、500mLのDMEM(SIGMA, D5671)、15%FCS(PAA, A15-251)、4mM L-グルタミン(SIGMA, G7513)、1%HES(SIGMA H6020)、1%ペニシリン/ストレプトマイシン(SIGMA, P0781)培地中で培養した。この最後の培養は、Hyperflask(Corning, 10030)内で、37℃、5%CO2にて10±1日行った。
LaemmLi緩衝液(Biotem)で予め稀釈した抗体(0.2μg/μLを5μL)を、95℃にて5分間加熱した。次に、スタッキングゲルおよび5%SDS-PAGEを含んでいる13.5%ドデシル硫酸ナトリウム-ポリアクリルアミドゲル電気泳動(SDS-PAGE)で分離した。ゲル中を90Vにて30分間、次に120Vにて2時間泳動させた。タンパク質の検出は、染色液(Biotem)を用いて、撹拌しながら1時間行った。ゲルを脱色液(Biotem)で撹拌しながら、1時間洗浄した。
[1.5.1.ELISAによるアイソタイピング]
maxisorp 96円錐底ウェルプレート(NUNC, 449824)を、50μLの1μg/mL抗マウス免疫グロブリン(Clinisciences, 1010-01)で、室温にて一晩コーティングした。プレートを、[1×PBS+0.05%Tween20]洗浄バッファで洗浄した(300μL/ウェル)。非特異的結合部位を、[1×PBS+0.05%Tween20+2.5%ミルク]ブロッキングバッファで、室温にて1時間ブロッキングした(150μL/ウェル)。プレートを、[1×PBS+0.05%Tween20]洗浄バッファで洗浄した(300μL/ウェル)。ハイブリドーマ上清を、[1×PBS+0.05%Tween20+0.5%BSA]稀釈バッファで、1:10に稀釈した。サンプルを、室温にて2時間インキュベートした(50μL/ウェル)。プレートを、[1×PBS+0.05%Tween20]洗浄バッファで1回洗浄した(300μL/ウェル)。次に、1×PBS+0.05%Tween20+0.5%BSA中で1/2000に稀釈した、ペルオキシダーゼ結合ヤギ抗マウス重鎖(IgA、IgG1、IgG2a、IgG2b、IgG3、IgM)(Clinisciences, 5300-05)と共に、室温にて1時間インキュベートした(50μL/ウェル)。プレートを1回洗浄し、TMB(Eurobio, 52-00-01)基質溶液を用いて、室温にて10分間発色させた(50μL/ウェル)。0.1M H2SO4(Merck, 1.12080.1000)停止液で、反応を停止させた(50μL/ウェル)。光学密度(OD)リーダ(Dynex)を用いて、450nmにおける光学密度(OD)を測定した。
軽鎖(κまたはλ)を、ラテラルフローイムノアッセイ(LFIA;ThermoFisher,26179)で特徴付けた。
ヒト胚細胞(1.106細胞/mL)を、1μgのHERV-K-Env(アクセッション番号:AY037928.1)発現プラスミドでトランスフェクトした。トランスフェクトした細胞を、37℃、8%CO2、120rpmで撹拌しながら培養した。
12.5ng/μLの組換えHERV-K-Envタンパク質(Mybiosource)と、1.5μg/μLのHEKトランスフェクト細胞由来タンパク質溶解物とを、2×LaemmLi緩衝液(SIGMA, S3401)で1:1に稀釈し、90℃にて5分間加熱した。次に、32μLのサンプルを、8~16%ドデシル硫酸ナトリウム-ポリアクリルアミドゲル電気泳動(SDS-PAGE;Novex, EC60452BOX)にロードした。ゲルを1×Tris-グリシンSDS泳動バッファ(Novex, LC2675)に入れ、160mAにて1時間泳動させた。1×Tris-グリシン転写バッファ(Novex, LC3675)中で、0.2μmニトロセルロース膜(Biorad, 162-0146)上にタンパク質を転写した。その後、この膜を、[1×PBS+5%ミルク(La Vie Claire)]ブロッキングバッファ中で、室温にて回転台に載せながら1時間ブロッキングした。GN_mAb_Env_K01ハイブリドーマ由来の細胞上清を[1×PBS+1%乳汁]抗体稀釈液で1:5に稀釈し、これで1時間インキュベートすることにより、一次抗体とした。次に、膜を[1×PBS+0.05%Tween20(SIGMA, P7949)]洗浄バッファ中で5分間、3回洗浄した。次に、1:1000に稀釈したHRP結合ヤギ抗マウスIgG抗体(Jackson, 115035-146)と共に、30分間インキュベートした。膜を3回洗浄し、提供されているプロトコルに則って、目的のタンパク質を比色反応(Opti 4-CN,Biorad,170-8235)で検出した。
エピトープマッピングは、Pepscan Presto BV(Zuidersluisweg 2, 8243RC Lelystad, The Netherlands)で行った。
標的分子のエピトープを再構築するために、ペプチドライブラリーを合成した。(i)製造者独自の親水性ポリマー物質をグラフトし、(ii)ジシクロヘキシルカルボジイミド(DCC)およびNヒドロキシベンゾトリアゾール(HOBt)を用いて、t-ブチルオキシカルボニル-ヘキサメチレンジアミン(BocHMDA)と反応させ、(iii)トリフルオロ酢酸(TFA)を用いてBoc基を切断することによって、アミノ官能化ポリプロピレン支持体を得た。標準的なFmoc-ペプチド合成により、アミノ官能化固相支持体上でペプチドを合成した。このとき、自己改造したJANUS liquid handling stations(Perkin Elmer)を使用した。構造模倣物の合成には、Pepscan独自のChemicallynked Peptides on Scaffolds(CLIPS)技術を用いた。CLIPS技術ならば、ペプチドを構造化して、一重ループ、二重ループ、三重ループ、シート状折畳み、らせん状折畳み、およびその組合せにすることができる。CLIPSテンプレートは、システイン残基に連結している。ペプチド中の複数のシステインの側鎖が、1個または2個のCLIPSテンプレートと連結する。一例として、P2 CLIPS(2,6-ビス(ブロモメチル)ピリジン)の0.5mM溶液を、重炭酸アンモニウム(20mM、pH7.8)/アセトニトリル(1:3(v/v))に溶解させる。この溶液を、ペプチドアレイ上に注入する。CLIPSテンプレートは、ペプチドアレイの固相に結合しているペプチド中に存在している、2つのシステイン側鎖と結合する(455ウェルのプレート;1ウェルあたり3μL)。ペプチドアレイを、溶液中で30~60分間穏やかに振盪する。このとき、ペプチドアレイが溶液に完全に覆われるようにする。最後に、ペプチドアレイを過剰のH2Oで充分に洗浄する。次に、PBS(pH7.2)中に1%SDS/0.1%β-メルカプトエタノールを含んでいる破砕バッファ中で、70℃にて30分間超音波処理し、その後、H2O中でさらに45分間超音波処理する。ペプチドを担持させるT3 CLIPSも同様の方法で作製したが、これは3つのシステインを用いた。
合成ペプチドの各々に対する抗体の結合を、Pepscan系ELISAで試験した。ペプチドアレイを、一次抗体溶液(Pepscanバッファ中に1μg/mLのGN_mAb_Env_K01)と共に、4℃にて一晩インキュベートした。洗浄後、ペプチドアレイを、1/1000に稀釈したウサギ抗マウスIgG(H+L)HRP結合抗体(Southern Biotech;表4)と共に、25℃にて1時間インキュベートした。洗浄後、ペルオキシダーゼ基質である2,2’-アジノ-ジ-3-エチルベンズチアゾリンスルホン酸(ABTS)と、20μL/mLの3%H2O2とを加えた。1時間後、発色を測定した。発色は、電荷結合素子カメラ(CCDカメラ)および画像加工システムを用いて、発色を定量化した。CCDカメラから得られた値は、標準的な96ウェルプレートELISAリーダと同じく、0~3000mAUの範囲である。
高品質なRNAを、PureLink RNA Mini Kit(Life technologies, 12183018A)を用いてハイブリドーマ細胞から抽出して精製し、アガロースゲル上で扱った。精製したRNAの全量を出発物質として、Superscript酵素(Invitrogen, 18064022)を使用して、第1鎖に相補的なDNA(cDNA)を合成した。次に、HotStar HiFidelity Polymerase Kit(Qiagen, 202602)と、マウス抗体の重鎖および軽鎖をコードしているcDNAを特異的に標的とする縮重プライマー(Biotem design)とを使用して、ポリメラーゼ連鎖反応(PCR)を施した。PCR産物はアガロースゲル上で扱い、配列を決定した(2本鎖配列を決定)。得られた配列を、専用のバイオインフォマティクスツール(Blast-ClustalW)を用いて集合および品質管理に関して分析し、ペプチド配列に翻訳した。
モノクローナル抗体の様々な重鎖および軽鎖を検出できる特異的な抗免疫グロブリン抗体を用いたところ、GN_mAb_Env_K01は、抗κ軽鎖抗体(図1A)および抗IgG2b重鎖(図1B)によって検出された。
HERV-K-Envタンパク質(Mybiosource製)を短縮した配列である529ペプチドのパネル(シグナルペプチドがなく、膜貫通ドメインが切断されている)を用いて、高ストリンジェンシー条件下にてエピトープマッピング試験を行った。この試験によって明らかになったところによると、GN_mAb_Env_K01抗体は、「SLDKHKHKKLQSFYP」というコア配列を有している直鎖ペプチドに結合する(図3左パネル)。このエピトープは、HERV-K-Envタンパク質の細胞外ドメイン内に含まれている(図3右パネル)。また、この配列は、Dewannieux et al(Dewannieux, Blaise, and Heidmann 2005)が報告したHERV-K-Envタンパク質の、298~312の領域に対応している。このエピトープを、National Center for Biotechnology Information(NCBI)のBlastpで検索すると、HERV-K-Env配列に対応する上位100件のヒット配列において100%の相同性を有している、高度に保存されたエピトープであることが明らかになる(データ不図示)。
GN_mAb_Env_K01がグリコシル化されたHERV-K-Envを認識する能力を、さらに分析した。この目的のために、ヒト胚腎臓細胞(HEK細胞)を、HERV-K-Envタンパク質をコードしているプラスミドでトランスフェクトした。種々の緩衝液を用いて何度か試みたものの、可溶性のHERV-K-Envタンパク質は抽出できなかった(データ不図示)。しかし、トランスフェクトされたHEK細胞溶解物に由来するグリコシル化されたHERV-K-Envタンパク質の不溶性断片が示すところによると、GN_mAb_Env_K01は、ELISAにおいて、グリコシル化されたHERV-K-Env抗原を特異的に認識している可能性がある(図4左パネル)。逆に、従来市販の抗HERV_K_Env_mAb(HERM-1821-5, IgG2b;AMSBIO製)は、グリコシル化されたHERV-K-Envを検出しなかった(図4右パネル)。
本報告により明らかになったところによると、マウスの免疫化、抗体のスクリーニング、およびモノクローナルハイブリドーマの選抜を経た後、HERV-K-Envのエピトープ:SLDKHKHKKLQSFYPを認識するマウスモノクローナル抗体(命名:GN_mAb_Env_K01)が開発された。また、この抗体は、予期しない特性を示すことも明らかになった。
[1.材料および方法]
[1.1.ヒトニューロン細胞]
ヒト神経幹細胞(NSC)由来の培養ニューロン細胞を、既報の通り用意した(Efthymiou, Shaltouki et al. 2014)。要約すると、以下の通りである。まず、0.002%ポリ-L-オルニチン(Sigma, St. Louis, MO)および10μg/mLラミニン(Life Technologies)でコーティングした96ウェルプレートにNSCを分割した(7500~10,000細胞/cm2)。播種から24時間後に、ニューロン分化培地を添加した。分化培地はDMEM/F12を含んでおり、GlutaMax、1.8%ウシ血清アルブミン(BSA)、1×StemPro hESC supplement(全てLife Technologies製)、10ng/mL脳由来神経栄養因子(BDNF)、およびグリア細胞下部由来神経栄養因子(GDNF;R&D Systems, Minneapolis, MN)を添加した。7~12日目のニューロンを、in vitroにて、神経毒性アッセイに利用した。
[1.2.1.ニューロンの形態および生存率]
Td-トマト蛍光タンパク質を定常的に発現させて細胞およびプロセスを標識化してある培養ヒトニューロン細胞(15,000~20,000細胞/ウェル)を、上述のように96ウェルプレートに播種した。このプレートを、5%CO2、湿潤条件下の組織培養インキュベーター中で37℃にて維持した。培養ニューロン細胞を、分化培地(上述)と、IgGサンプルGN_K01または対照非免疫IgG(Thermo Product # MA 1-10418)で処理した(最終濃度:3μg/mL)。60分のプレインキュベート後、組換えHERV-K-Envタンパク質(My BioSource, amino acid 90-632, Cat # MBS1391552)を添加した(最終濃度:100nM)。GN_K01 Igの1つのサンプルを、HERV-K-Envと共に30分間プレインキュベートした後、一緒にヒトニューロンに加えた。培養ニューロン細胞をGE INCell Analyzer 2000 BioImagerで観察して、様々な時点における各ウェルの画像を得た(処理後24時間、48時間、72時間。1ウェルあたり4枚の画像)。この培養細胞のハイコンテントな撮像および分析には、GE Investigator 1.93分析ソフトウェアを用いた。ニューロン生存率、神経突起長および他の形態学的パラメータを、サンプルごとに定量化した。Graph Pad Prism 7.02でデータを描画した。
Axion Maestro微小電極アレイアッセイ(MEAアッセイ)による電気生理学的分析
48ウェルt-MEAプレートに培養ヒトニューロン細胞を播種して分析した。このプレートには、1ウェルあたり16個の活動記録電極が設けられている。200,000個のニューロンをt-MEAプレートの各ウェルに注入し、培養物を5%CO2、湿潤条件下の組織培養インキュベーター中で37℃にて維持した。電気生理学的活動(ウェル中のスパイク発生率の増加によって示される)は、第21日までにin vitroにおいて有意に上昇した。電気生理学的活動は、1日あたり5分間、全てのウェル中の自発的な電気活動を記録することによってモニタリングした。この時点で、培養ヒトニューロン細胞を、分化培地(上述)と、IgGサンプルのGN_K01または対照の非免疫IgG(Thermo Product # MA 1-10418)と、で処理した(最終濃度:3μg/mL)。60分間プレインキュベートした後、組換えHERV-K-Envタンパク質(My BioSource)を加えて、最終濃度を100nMとした。上述の条件において、抗体は、初めにEnvを含んでいない細胞に添加される。そのため、「患者の脳組織中に治療抗体が拡散して存在している」という処置された患者の状態が再現されている。その後、活性なEnvタンパク質を添加する(このタンパク質は、抗体と一緒にプレインキュベートされておらず、「事前に中和」されておらず、不活性なタンパク質として添加されない)。これにより、細胞外空間における細胞外分泌を伴う病原性タンパク質の発現が再現されている。GN_K01 Igの1つのサンプルを、HERV-K-Envと共に30分間プレインキュベートした後、一緒にヒトニューロンに加えた。処理後24時間から、自発的な電気活動を毎日記録した。電気的活動の定量化には、Axion Axisソフトウェアを用いた。スパイク数、平均発火率およびバースト数などのパラメータを、処理ごとに決定した。
[2.1.細胞外HERV-Kエンベロープタンパク質はヒトニューロン細胞に対して毒性があり、その毒性はGN_mAb_Env_K01(GN_K01)抗体によって特異的に阻害される]
[2.1.1.ニューロンの生存率]
100nMの組換えHERV-K-Envタンパク質で処理した培養ヒトニューロン細胞では、有意な神経毒性が示された。その結果、翌日までに重大なニューロン細胞の損失が生じた。HERV-K-Envタンパク質への曝露から5日後に、HERV-K-Envの効果を定量化した。EnvおよびGN_K01 Ig(3μg/mL)で処理したニューロンは、Envで処理ニューロンと比較して、生存率が向上していたことが観察された。HERV-Kエンベロープタンパク質を培地に添加した5日後に分析したところ、Envおよび非免疫IgG対照抗体(3μg/mL)で処理した細胞では、同様の毒性が示された。GN_K01(3μg/mL)で処理したニューロンは、(i)HERV-K-Envに先立って処理したものであっても、(ii)Envと共にプレインキュベートした後、培養ニューロン細胞適用されたものであっても、ニューロンの生存率をさらに有意に向上させた。これによって、GN_K01抗体のHERV-K-Envタンパク質の毒性を中和する効果が確認された(図7)。
平均神経突起長に対するHERV-K-Envの影響を、並行して分析した。Envに曝露したニューロンに対してGN_K01(3μg/mL)を添加すると、Envで処理したニューロンまたはEnvおよび対照非免疫Igで処理した処理ニューロンと比較して、神経突起長が有意に増加した(図8)。
Axion Maestro MEAシステムを用いた電気生理学的研究によって、HERV-K-Env処理が、自発的な電気活動(正常なニューロン活動の主要な特徴)に対する機能的変化を生じさせたか否かを評価した。48ウェルMEAプレートに培養ヒトニューロン細胞を播種してから21日後、(i)分化培地(上述)および(ii)GN_K01または対照非免疫IgG(Thermo Product # MA 1-10418)、の中で培養細胞をインキュベートした(最終濃度:3μg/mL)。60分のプレインキュベート後、組換えHERV-K-Envタンパク質(My BioSource, Cat # MBS1391552)を添加した(最終濃度:100nM)。GN_K01 Igの1つのサンプルを、HERV-K-Envと共に30分間プレインキュベートした後、一緒にヒトニューロンに加えた。処理後24時間から、自発的な電気活動を記録した。HERV-K-Envによる処理後24時間において、Envで処理したニューロンは、スパイク数および平均発火率が40%減少した。HERV-K-Envおよび対照非免疫IgG処理に曝露したニューロンは、スパイク数および平均発火率が約30%減少した。最も興味深いことに、HERV-K-EnvおよびGN_K01に曝露したニューロンは、コントロール培地のみでインキュベートしたウェルと同様のスパイク数および平均発火率を示した。このことから、全体的なニューロンの機能活動に対するHERV-K-Envの病原性効果が、完全に阻害されたことが示される(図9)。
したがって、GN_K01抗体の効力は特異的である。ニューロンをHERV-K-Envタンパク質に曝露した結果生じる病原性に対する有利な効果は、以下の有意なデータによって立証された。(i)細胞死を阻害する。(ii)ニューロン細胞の形態および神経突起長を維持する。(iii)無関係な対照抗体を用いて(または、抗体を用いずに)HERV-K-Envに対して曝露したニューロンと比較して、HERV-K-Envタンパク質の病原性の存在下における電気生理学的活動によって測定されるニューロンの機能活動を、完全に回復させる。
Alfahad, T., and A. Nath. 2013. 'Retroviruses and amyotrophic lateral sclerosis', Antiviral Res, 99: 180-7.
Andrews, W. D., P. W. Tuke, A. Al-Chalabi, P. Gaudin, S. Ijaz, M. J. Parton, and J. A. Garson. 2000. 'Detection of reverse transcriptase activity in the serum of patients with motor neurone disease', J Med Virol, 61: 527-32.
Buratti, E., and F. E. Baralle. 2009. 'The molecular links between TDP-43 dysfunction and neurodegeneration', Adv Genet, 66: 1-34.
Dewannieux, M., S. Blaise, and T. Heidmann. 2005. 'Identification of a functional envelope protein from the HERV-K family of human endogenous retroviruses', J Virol, 79: 15573-7.
Douville, R., J. Liu, J. Rothstein, and A. Nath. 2011. 'Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis', Ann Neurol, 69: 141-51.
Douville, R. N., and A. Nath. 2014. 'Human endogenous retroviruses and the nervous system', Handb Clin Neurol, 123: 465-85.
Duperray, A., D. Barbe, G. Raguenez, B. B. Weksler, I. A. Romero, P. O. Couraud, H. Perron, and P. N. Marche. 2015. 'Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4', Int Immunol, 27: 545-53.
Efthymiou, A., A. Shaltouki, J. P. Steiner, B. Jha, S. M. Heman-Ackah, A. Swistowski, X. Zeng, M. S. Rao and N. Malik (2014). "Functional screening assays with neurons generated from pluripotent stem cell-derived neural stem cells." J Biomol Screen 19(1): 32-43.
Geser, F., M. Martinez-Lage, L. K. Kwong, V. M. Lee, and J. Q. Trojanowski. 2009. 'Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases', J Neurol, 256: 1205-14.
Hardiman, O., L. H. van den Berg, and M. C. Kiernan. 2011. 'Clinical diagnosis and management of amyotrophic lateral sclerosis', Nat Rev Neurol, 7: 639-49.
Lagier-Tourenne, C., and D. W. Cleveland. 2009. 'Rethinking ALS: the FUS about TDP-43', Cell, 136: 1001-4.
Li, W., M. H. Lee, L. Henderson, R. Tyagi, M. Bachani, J. Steiner, E. Campanac, D. A. Hoffman, G. von Geldern, K. Johnson, D. Maric, H. D. Morris, M. Lentz, K. Pak, A. Mammen, L. Ostrow, J. Rothstein, and A. Nath. 2015. 'Human endogenous retrovirus-K contributes to motor neuron disease', Sci Transl Med, 7: 307ra153.
MacGowan, D. J., S. N. Scelsa, T. E. Imperato, K. N. Liu, P. Baron, and B. Polsky. 2007. 'A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS', Neurology, 68: 1944-6.
Mallet, F., O. Bouton, S. Prudhomme, V. Cheynet, G. Oriol, B. Bonnaud, G. Lucotte, L. Duret, and B. Mandrand. 2004. 'The endogenous retroviral locus ERVWE1 is a bona fide gene involved in hominoid placental physiology', Proc Natl Acad Sci U S A, 101: 1731-6.
Manghera, M., J. Ferguson-Parry, and R. N. Douville. 2016. 'TDP-43 regulates endogenous retrovirus-K viral protein accumulation', Neurobiol Dis, 94: 226-36.
McCormick, A. L., R. H. Brown, Jr., M. E. Cudkowicz, A. Al-Chalabi, and J. A. Garson. 2008. 'Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate', Neurology, 70: 278-83.
Moulignier, A., A. Moulonguet, G. Pialoux, and W. Rozenbaum. 2001. 'Reversible ALS-like disorder in HIV infection', Neurology, 57: 995-1001.
Oluwole, S. O., Y. Yao, S. Conradi, K. Kristensson, and H. Karlsson. 2007. 'Elevated levels of transcripts encoding a human retroviral envelope protein (syncytin) in muscles from patients with motor neuron disease', Amyotroph Lateral Scler, 8: 67-72.
Perron, H., J. P. Perin, F. Rieger, and P. M. Alliel. 2000. 'Particle-associated retroviral RNA and tandem RGH/HERV-W copies on human chromosome 7q: possible components of a 'chain-reaction' triggered by infectious agents in multiple sclerosis?', J Neurovirol, 6 Suppl 2: S67-75.
Polymenidou, M., and D. W. Cleveland. 2011. 'The seeds of neurodegeneration: prion-like spreading in ALS', Cell, 147: 498-508.
Rolland, A., E. Jouvin-Marche, C. Viret, M. Faure, H. Perron, and P. N. Marche. 2006. 'The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses', J Immunol, 176: 7636-44.
Rosen, D. R. 1993. 'Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis', Nature, 364: 362.
Steele, A. J., A. Al-Chalabi, K. Ferrante, M. E. Cudkowicz, R. H. Brown, Jr., and J. A. Garson. 2005. 'Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives', Neurology, 64: 454-8.
Taylor, J. P., R. H. Brown, Jr., and D. W. Cleveland. 2016. 'Decoding ALS: from genes to mechanism', Nature, 539: 197-206.
Turner, G., M. Barbulescu, M. Su, M. I. Jensen-Seaman, K. K. Kidd, and J. Lenz. 2001. 'Insertional polymorphisms of full-length endogenous retroviruses in humans', Curr Biol, 11: 1531-5.
von Giesen, H. J., R. Kaiser, H. Koller, K. Wetzel, and G. Arendt. 2002. 'Reversible ALS-like disorder in HIV infection. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy', Neurology, 59: 474; author reply 74-5.
Vucic, S., and M. C. Kiernan. 2009. 'Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis', Curr Mol Med, 9: 255-72.
Claims (9)
- K型ヒト内在性レトロウイルス(HERV-K)エンベロープタンパク質を認識する抗体であって、
上記抗体は、配列番号9に記載のエピトープに結合し、
上記抗体は、
3つの相補性決定領域(CDR-L1、CDR-L2およびCDR-L3)を有している軽鎖可変領域(VL)を有する軽鎖と、
3つの相補性決定領域(CDR-H1、CDR-H2およびCDR-H3)を有している重鎖可変領域(VH)を有する重鎖と、
を有しており、
上記CDR-L1は配列番号1に記載のアミノ酸配列を含み、上記CDR-L2は配列番号2に記載のアミノ酸を含み、上記CDR-L3は配列番号3に記載のアミノ酸配列を含み、上記CDR-H1は配列番号4のアミノ酸配列を含み、上記CDR-H2は配列番号5のアミノ酸配列を含み、上記CDR-H3は配列番号6のアミノ酸配列を含む、
抗体。 - 上記軽鎖可変領域(VL)は、配列番号7に記載のアミノ酸配列を含んでおり、
上記重鎖可変領域(VH)は、配列番号8に記載のアミノ酸配列を含んでいる、
請求項1に記載の抗体。 - 上記抗体は、モノクローナル抗体である、請求項1または2に記載の抗体。
- 上記抗体は、マウスモノクローナル抗体、キメラモノクローナル抗体またはヒト化モノクローナル抗体である、請求項1~3のいずれか1項に記載の抗体。
- 治療における使用のための、請求項1~4のいずれか1項に記載の抗体。
- 筋萎縮性側索硬化症(ALS)の処置のための、請求項1~4のいずれか1項に記載の抗体を含んでいる医薬組成物。
- 上記筋萎縮性側索硬化症(ALS)は散発性ALSである、請求項6に記載の医薬組成物。
- 請求項1~4のいずれか1項に記載の抗体と、薬学的に許容可能な賦形剤と、を含んでいる、医薬組成物。
- 生体サンプル中のHERV-Kエンベロープタンパク質を検出するin vitroの方法であって、
上記生体サンプルを、請求項1~4のいずれか1項に記載の抗HERV-Kエンベロープ抗体と接触させる工程を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305062.6 | 2017-01-20 | ||
EP17305062.6A EP3351265A1 (en) | 2017-01-20 | 2017-01-20 | Anti-herv-k envelope antibody and uses thereof |
PCT/US2018/014489 WO2018136775A1 (en) | 2017-01-20 | 2018-01-19 | Anti-herv-k envelope antibody and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020505383A JP2020505383A (ja) | 2020-02-20 |
JP7139340B2 true JP7139340B2 (ja) | 2022-09-20 |
Family
ID=58018037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019539822A Active JP7139340B2 (ja) | 2017-01-20 | 2018-01-19 | 抗herv-kエンベロープ抗体およびその使用 |
Country Status (15)
Country | Link |
---|---|
US (2) | US10723787B2 (ja) |
EP (2) | EP3351265A1 (ja) |
JP (1) | JP7139340B2 (ja) |
KR (1) | KR102599010B1 (ja) |
CN (1) | CN110678196B (ja) |
AR (1) | AR110949A1 (ja) |
AU (1) | AU2018210388B2 (ja) |
BR (1) | BR112019014773A8 (ja) |
CA (1) | CA3050286A1 (ja) |
EA (1) | EA039460B1 (ja) |
IL (1) | IL267955A (ja) |
MX (1) | MX2019008648A (ja) |
TW (1) | TWI793098B (ja) |
UA (1) | UA126677C2 (ja) |
WO (2) | WO2018136775A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3351265A1 (en) * | 2017-01-20 | 2018-07-25 | Geneuro SA | Anti-herv-k envelope antibody and uses thereof |
EP4025303A1 (en) * | 2019-09-04 | 2022-07-13 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Herv inhibitors for use in treating tauopathies |
WO2023212587A1 (en) * | 2022-04-28 | 2023-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160087A1 (en) | 2003-01-31 | 2006-07-20 | Mcgrath Michael | Monitoring and treatment of amyotrophic lateral sclerosis |
WO2013059426A1 (en) | 2011-10-21 | 2013-04-25 | The Regents Of The University Of California | Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
US20150250864A1 (en) | 2012-06-25 | 2015-09-10 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2273099A (en) * | 1992-11-10 | 1994-06-08 | Asta Medica Ag | Glycoprotein encoded by a human endogenous retrovirus K envelope gene |
FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
US20090297530A1 (en) * | 2006-05-22 | 2009-12-03 | Feng Wang-Johanning | Herv-k antigens, antibodies, and methods |
FR2912314B1 (fr) * | 2007-02-09 | 2012-08-03 | Geneuro Sa | Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w. |
UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
CN103755805B (zh) * | 2014-02-11 | 2015-08-12 | 中国疾病预防控制中心病毒病预防控制所 | HIV-1 Env特异性的全人单克隆抗体 |
EP3355924A1 (en) * | 2015-09-29 | 2018-08-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of treating and preventing amyotrophic lateral sclerosis |
WO2018044970A1 (en) * | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
EP3351265A1 (en) * | 2017-01-20 | 2018-07-25 | Geneuro SA | Anti-herv-k envelope antibody and uses thereof |
-
2017
- 2017-01-20 EP EP17305062.6A patent/EP3351265A1/en not_active Withdrawn
-
2018
- 2018-01-19 UA UAA201909194A patent/UA126677C2/uk unknown
- 2018-01-19 WO PCT/US2018/014489 patent/WO2018136775A1/en unknown
- 2018-01-19 US US16/478,576 patent/US10723787B2/en active Active
- 2018-01-19 EP EP18713060.4A patent/EP3570878A1/en active Pending
- 2018-01-19 BR BR112019014773A patent/BR112019014773A8/pt unknown
- 2018-01-19 AR ARP180100129A patent/AR110949A1/es unknown
- 2018-01-19 WO PCT/US2018/014479 patent/WO2018136774A1/en active Application Filing
- 2018-01-19 AU AU2018210388A patent/AU2018210388B2/en active Active
- 2018-01-19 CA CA3050286A patent/CA3050286A1/en active Pending
- 2018-01-19 MX MX2019008648A patent/MX2019008648A/es unknown
- 2018-01-19 KR KR1020197024261A patent/KR102599010B1/ko active IP Right Grant
- 2018-01-19 JP JP2019539822A patent/JP7139340B2/ja active Active
- 2018-01-19 CN CN201880014059.2A patent/CN110678196B/zh active Active
- 2018-01-19 EA EA201991736A patent/EA039460B1/ru unknown
- 2018-01-22 TW TW107102219A patent/TWI793098B/zh active
-
2019
- 2019-07-09 IL IL267955A patent/IL267955A/en unknown
-
2020
- 2020-06-17 US US16/903,947 patent/US10981977B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160087A1 (en) | 2003-01-31 | 2006-07-20 | Mcgrath Michael | Monitoring and treatment of amyotrophic lateral sclerosis |
WO2013059426A1 (en) | 2011-10-21 | 2013-04-25 | The Regents Of The University Of California | Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
US20150250864A1 (en) | 2012-06-25 | 2015-09-10 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
Non-Patent Citations (1)
Title |
---|
LI W,HUMAN ENDOGENOUS RETROVIRUS-K CONTRIBUTES TO MOTOR NEURON DISEASE,SCIENCE TRANSLATIONAL MEDICINE,2015年09月30日,VOL:7, NR:307,PAGE(S):307RA153/1-12,https://stm.sciencemag.org/content/7/307/307ra153/tab-pdf |
Also Published As
Publication number | Publication date |
---|---|
CN110678196B (zh) | 2024-03-12 |
CA3050286A1 (en) | 2018-07-26 |
BR112019014773A8 (pt) | 2020-06-09 |
EA201991736A1 (ru) | 2019-12-30 |
AR110949A1 (es) | 2019-05-22 |
TWI793098B (zh) | 2023-02-21 |
WO2018136775A1 (en) | 2018-07-26 |
EP3570878A1 (en) | 2019-11-27 |
MX2019008648A (es) | 2019-12-02 |
US10723787B2 (en) | 2020-07-28 |
JP2020505383A (ja) | 2020-02-20 |
TW201831518A (zh) | 2018-09-01 |
IL267955A (en) | 2019-09-26 |
EA039460B1 (ru) | 2022-01-28 |
AU2018210388B2 (en) | 2024-05-23 |
WO2018136774A1 (en) | 2018-07-26 |
US20200308258A1 (en) | 2020-10-01 |
US20190345232A1 (en) | 2019-11-14 |
US10981977B2 (en) | 2021-04-20 |
KR20190119593A (ko) | 2019-10-22 |
KR102599010B1 (ko) | 2023-11-06 |
UA126677C2 (uk) | 2023-01-11 |
AU2018210388A1 (en) | 2019-08-01 |
EP3351265A1 (en) | 2018-07-25 |
CN110678196A (zh) | 2020-01-10 |
BR112019014773A2 (pt) | 2020-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7143452B2 (ja) | CD47とSIRPaの相互作用を遮断できる抗体及びその応用 | |
JP7173618B2 (ja) | アルファ-シヌクレインに対する抗体およびその用途 | |
JP7034499B2 (ja) | 線維症の治療のための抗fam19a5抗体の用途 | |
US10981977B2 (en) | Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis | |
AU2017384681A1 (en) | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation | |
JP2022023050A (ja) | 併用療法 | |
US20220049009A1 (en) | Anti-Abeta Antibodies | |
NZ796415A (en) | Anti-herv-k envelope antibody and uses thereof | |
US10654925B2 (en) | Anti-marinobufagenin antibodies and uses thereof | |
US20230212271A1 (en) | Compositions and methods for linear and conformational site-specific antibodies and methods of making the same | |
US20230287090A1 (en) | USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19 | |
TW202200623A (zh) | 對炎症性腸病之治療用抗體 | |
TW202400643A (zh) | 神經退化性疾病之治療劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191008 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220830 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220907 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7139340 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |